Accord Healthcare, a generic pharmaceutical company, has added Vilazodone to its oral tablets portfolio. The drug is therapeutically equivalent to Allergan's VIIBRYDR and approved to treat major depressive disorder (MDD) in adults. Accord's product, offered in 10 mg, 20 mg, and 40 mg tablets, is currently available to ship.
Depression is a leading cause of disability worldwide. Not only does it cause mental and emotional suffering that largely goes untreated in many countries, but depression also contributes to physical disease and can impact the prognosis of major diseases, including heart disease and cancer.
Vilazodone was FDA-approved for major depressive disorder in adults in 2011.